Announcements

Headache Update—2000

Disney's Grand Floridian Resort & Spa, Lake Buena Vista, Florida (Disney world)

18–22 July, 2000

Approved 21.5 credit hours Category 1. Fees: $350.00 for physician, psychologist, dentist; $250.00 for RN, other allied health professional; $155.00 for interns, residents. Abstracts accepted for scientific posters.

For further information contact: tel [phone]; fax [phone].

10th International Headache Research Seminar

The Triptans: Novel Drugs For Migraine

Organizers: Patrick P. A. Humphrey, Michel Ferrari and Jes Olesen

Copenhagen, 1–3 December, 2000

Friday, 1 December, 2000

Session I, Background and early development

1. (1)

   Discovery of sumatriptan and its 5-HT receptor selectivity. Patrick A. Humphrey (20 min)

2. (2)

   Location of 5-HT receptors in brain and vasculature. Richard Hargreaves (20 min)

3. (3)

   5-HT receptor transduction mechanisms and functions. Graeme Martin (20 min)

Posters on these aspects (60 min)

Discussion (60 min)

Session II, Pharmacology of the triptans

Pharmacokinetics of the triptans. David Milson (20 min)

1. (1)

   Pharmacodynamics of the triptans. Pramod Saxena (20 min)

2. (2)

   Characteristics of different routes of administration. Carl Dahlöf (20 min)

Posters on the pharmacology of triptans (60 min)

Discussion (60 min)

Saturday, 2 December, 2000

Session III, Anti-migraine actions of the triptans

1. (1)

   Cranial vasoconstriction is most important. Wasyl Feniuk (15 min)

2. (2)

   Inhibition of neurogenic inflammation is most important. TBA (15 min)

3. (3)

   Central nervous system effects are most important. Peter Goadsby (15 min)

4. (4)

   Do we really understand the antimigraine effect of the triptans? Jes Olesen (15 min)

Posters on the mechanisms of action of triptans (30 min)

Discussion (60 min)

Session IV, Clinical efficacy and tolerability of the triptans, Part 1

1. (1)

   Sumatriptan. GlaxoWellcome (20 min)

2. (2)

   Zolmitriptan. Zeneca (20 min)

3. (3)

   Rizatriptan. Merck (20 min.)

Posters on these triptans (60 min)

Discussion (60 min)

Session V, Clinical efficacy and tolerability of the triptans, Part 2

1. (1)

   Naratriptan. GlaxoWellcome (20 min)

2. (2)

   Eletriptan. Pfizer (20 min)

3. (3)

   Almotriptan. UpJohn Pharmacia/Almiral (20 min)

4. (4)

   Frovatriptan. Vanguard Medical (20 min)

Posters on these triptans (60 min)

Discussion (60 min)

Sunday, 3 December, 2000

Session VI, The triptans in clinical practice

1. (1)

   Triptans vs. other treatments. Richard Lipton (20 min)

2. (2)

   Nine years of clinical experience with sumatriptan. Michel Ferrari (20 min)

3. (3)

   Which triptan for which patient? Peer Tfelt-Hansen (20 min)

Posters on comparative trials (60 min)

Extended general discussion (90 min)

For further information, please contact: Hanne Aggergaard, Secretary, Department of Neurology, Glostrup Hospital, Denmark. Tel [phone]; fax [phone]; e-mail: [e-mail]